

Published in final edited form as:

*Pediatr Allergy Immunol.* 2013 March ; 24(2): 122–130. doi:10.1111/pai.12049.

## Associations of postnatal weight and length/height gain with wheeze, asthma and atopy: The PROBIT Study

Emma L Anderson, BSc<sup>1</sup>, Abigail Fraser, PhD<sup>2</sup>, Richard M. Martin, PhD<sup>1,2</sup>, Michael S. Kramer, PhD<sup>3</sup>, Emily Oken, PhD<sup>4</sup>, Rita Patel, PhD<sup>2</sup>, and Kate Tilling, PhD<sup>2</sup>

<sup>1</sup>MRC Centre for Causal Analyses in Translational Epidemiology, School of Social and Community Medicine, University of Bristol, UK

<sup>2</sup>School of Social and Community Medicine, University of Bristol, Bristol, UK

<sup>3</sup>Dept. of Pediatrics & Dept. of Epidemiology, Biostatistics and Occupational Health, McGill University Faculty of Medicine, Montreal, Canada

<sup>4</sup>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, USA

### Abstract

**Background**—It has been hypothesised that postnatal weight and length/height gain are variously related to wheeze, asthma and atopy, however supporting evidence is limited and inconsistent.

**Methods**—Weights and lengths/heights of 12,171 term-infants were measured from birth to 12 months and at 6.5 years, and extracted from polyclinic records prospectively obtained between 12 and 60 months. Atopic phenotypes were ascertained at 6.5 years with the International Study of Asthma and Allergy in Childhood questionnaire and skin-prick tests. Logistic regression models investigated whether rates of weight and length/height gain from infancy to mid-childhood were associated with atopy phenotypes that have occurred ever or in the last 12 months.

**Results**—After controlling for confounders and prior weight and length/height gain, all weight gain variables except birthweight were positively associated with ever having wheezed ( $p < 0.1$ ). A one SD increase in weight gain rate between 0–3 months was associated with a 12% increase (2%–23%) in allergic rhinitis ever. No other consistent patterns of association were found for weight gain or length/height gain rate between 0–60 months with atopic outcomes at 6.5 years. In contrast, all atopy outcomes except for ever having asthma were associated with current weight and height, even after controlling for prior growth.

**Conclusion**—Current height and weight are more strongly associated with the development of atopic phenotypes in childhood than patterns of infant and early childhood growth, which may well reflect reverse causality (atopy effects on growth) or residual confounding by an unknown common cause of growth and atopy.

### Keywords

wheeze; asthma; atopy; postnatal growth; weight gain; length gain

---

**Correspondence to:** Emma Anderson, School of Social and Community Medicine, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK, Tel: + 44 7805 537 035, emma.louise.anderson@bristol.ac.uk.

**Competing interests:** The authors have no conflicts of interest to disclose

## INTRODUCTION

Prevalence rates and secular trends of asthma and atopy vary greatly between countries,<sup>1–10</sup> In Northern and Eastern Europe, asthma prevalence is reported to vary from 5.0% to 13.6%, and rhinoconjunctivitis from 2.0% to 13.0% among children aged 6–7 years,<sup>11</sup> Childhood asthma has been linked to increased doctor visits, school absenteeism and limited childhood activity,<sup>12</sup> whilst eczema and allergic rhinitis adversely affect quality of life. Identifying early-life risk factors for these diseases may present an opportunity for prevention.

A higher concordance of asthma and atopy in monozygotic than dizygotic twins implies a genetic component of the diseases,<sup>13</sup> but this cannot explain the steep increases in asthma/atopy rates observed in some regions,<sup>12</sup> or large variations in prevalence in genetically similar groups.<sup>11</sup> Low and high birth weight have been associated with asthma,<sup>14,15</sup> and atopy,<sup>16</sup> but this association may be confounded by factors such as poverty and inner-city residence.<sup>12</sup> Research on growth and asthma/atopy has focused largely on associations with fetal growth,<sup>17–19</sup> and on steroid treatment with subsequent growth in childhood.<sup>20–22</sup> Little focus has been placed on associations of postnatal weight and length/height gain with asthma and atopy, and published studies are inconclusive with positive,<sup>23–25</sup> negative,<sup>26,27</sup> and null associations reported.<sup>28</sup> Several studies to date have reported cross-sectional associations of weight with asthma in childhood.<sup>29–33</sup>

Between birth and 18 months of age there is a rapid increase in alveolar size and number and airway diameter continues to grow, so postnatal environmental influences have the potential to affect lung development.<sup>24</sup> We tested the hypothesis that weight and length/height gain between 0 and 60 months are associated with wheeze, asthma, allergic rhinitis, eczema and skin prick test results at 6.5 years, in a large contemporary cohort of term infants.

## METHODS

### Study population

The Promotion of Breastfeeding Intervention Trial (PROBIT) was a cluster randomised trial conducted in the Republic of Belarus, designed to investigate the effects of an intervention promoting prolonged and exclusive breastfeeding on infant and child health. Detailed methods have been previously reported.<sup>34</sup> Ethics approval was obtained from the Research Ethics Board of the Montreal Children's Hospital of the McGill University Health Centre. Participants were 17,046 mother-infant pairs, recruited between June 1996 and December 1997. To be eligible, neonates had to be full-term (> 37 weeks gestation), singleton, weigh at least 2500g, have an Apgar score  $\geq$  5 at 5 minutes, and have initiated breastfeeding.

At age 6.5 years, 13,889 (82%) children attended a follow-up research visit (PROBIT II).<sup>35–39</sup> Our study sample consists of 12,171 children who had complete data on all potential confounders, at least two measures of length/height and weight between birth and 60 months, weight and height at 6.5 years and at least one atopic outcome measure at 6.5 years.

### Exposures and confounders

Study paediatricians measured infants' weights and lengths at scheduled clinic visits at 1, 2, 3, 6, 9 and 12 months. At the 6.5 year study visit, weights and lengths/heights of children measured at routine check-ups between 12 and 60 months were abstracted from medical records and weight and height measured using standardized techniques.<sup>38</sup> At the 6.5 year visit, parental height and weight were recorded by interviewing the child's accompanying parent. As only 2% of mothers reported smoking during pregnancy, this variable was not included in the main analyses, but was included in the confounder-adjusted models as a

sensitivity analysis. Exclusive breastfeeding at 3 months, mother's age, family history of atopy, parent's education and urban or rural residence were self-reported. Family history of atopy included 6 binary variables stating whether the mother, father or an older sibling had ever had asthma, hay fever or eczema. Parent's education was categorised as 'completed university', 'advanced secondary/partial university', 'common secondary' and 'incomplete secondary'. Study treatment arm was included in all confounder-adjusted models.

## Outcomes

Atopy phenotypes were ascertained at the 6.5 year visit using the validated International Study of Asthma and Allergy in Childhood (ISAAC) questionnaire, translated into Russian.<sup>36</sup> The outcomes (binary variables) are: wheeze ever, wheeze in the last 12 months, allergic rhinitis ever, allergic rhinitis in the last 12 months, eczema ever and asthma ever. Skin prick tests to five antigens were conducted (see online supplement for details): house dust mite, cat, birch pollen, mixed northern grasses, and *Alternaria*. A binary variable was constructed contrasting those who had no positive reaction to any of the antigens, with those who had a positive reaction to one or more of the antigens.

## STATISTICAL ANALYSIS

### Individual growth trajectories

Individual length/height and weight gain trajectories were estimated using a multi-level model, fitted using MLwiN version 2.16. For both genders, a multilevel model for length/height was fitted, with linear gain between 0 and 3 months, 3 and 12 months, 12 and 34 months and 34 and 60 months. An equivalent model was fitted for weight. This is a similar model to that which has been used before in this dataset,<sup>40–42</sup> but with the addition of the extra knot point at 34 months which was found during recent data updating. Using these models, length/height and weight at birth and parameters of growth between the defined knot points were estimated for each individual. These were then standardised (z-scored) by gender. Birth length/height and weight were further standardised by gestational age.<sup>43</sup>

### Estimating associations between outcomes and weight and length/height gain rates

Logistic regression models allowing for clustering within clinics estimated associations of length/height and weight gain rates in from infancy to mid-childhood with all atopy phenotypes. Four models were fitted for each weight exposure: Model 1 adjusted for clustering by clinic only. Model 2 additionally adjusted for all potential confounders. Model 3 additionally included all preceding weight and length/height measurements. Similar models were fitted for length/height exposures, except that Model 2 additionally adjusted for birth weight, and model 3 only adjusted for preceding length/height, not weight. The independent effects of treatment arm allocation on asthma and other atopic outcomes in PROBIT have been reported previously.<sup>36</sup> Adjustment for the effect of the randomized treatment arm was achieved by including it as a covariate in all models. In secondary analyses, we examined mediation of these associations by weight and height at 6.5 years, mindful of the potential for collider bias (Model 4)<sup>44</sup>. Multivariable logistic models were fitted to examine associations of current weight and height at 6.5 years with all outcomes.

## RESULTS

12,065 (99%) children had all six scheduled weight and length/height measures up to and including one year. The median number of routine weight and length/height measures between 1 year and the 6.5 year follow-up was 4 (min 0, max 6). 9772 (80.3%) children had all atopic outcome measures at 6.5 years and 12,167 (99.9%) had missing data for only one outcome or less. As shown in Table 1, differences in some characteristics were observed

between those participants included in our analysis compared to those excluded due to missing data; however, the magnitude of the differences for each of these characteristics was small. On average, length/height and weight velocity was greater in boys than in girls during the first 3 months, after which growth velocities were similar (Table 2). At 6.5 years, boys were taller and heavier than girls.

The fully adjusted models are presented in Tables 3, 4 and 5, and minimally adjusted and confounder adjusted models in Web tables A, B and C in the online supplement. There was no evidence of interaction between sex and each period of weight and length/height gain velocity with any of the outcomes (Web tables D and E), thus, we report models in which the sexes were combined are reported and sex is adjusted for in these models. As expected, the addition of maternal smoking during pregnancy to the confounder adjusted models did not alter any of our findings (Web tables F and G), and no independent effect of study treatment arm on atopic phenotypes was observed (Web table H).

### **Associations of weight gain velocities with atopy phenotypes**

Overall, no consistent patterns of association were observed between weight gain rate and wheeze and asthma, or other atopy phenotypes in the fully adjusted model (Table 3). Weight gain velocity between 0 and 3 months and between 12 and 34 months was positively associated with ever having wheezed, and weight gain velocity between 0 and 3 months was positively associated with allergic rhinitis ever. Weight gain velocity from 12 to 34 months was inversely associated with skin prick test results, and weight gain velocity from 34 to 60 months was positively associated with skin prick test results. There was no evidence of associations of birth weight or weight gain rates in early childhood with wheeze in the last 12 months, asthma or eczema.

### **Associations of length/height gain velocities with atopy phenotypes**

There were no consistent patterns of association between birth length or length/height gain rate and wheeze and asthma, or other atopy phenotypes in the fully adjusted model (Table 4). Length/height gain velocity between 12 and 34 months was positively associated with wheeze ever. Length/height gain velocity between 0 and 3 months was positively associated with allergic rhinitis ever. There were no associations of birth length or subsequent length/height gain velocity with wheeze and allergic rhinitis in the previous 12 months, asthma or eczema ever or skin prick test results.

### **Associations of current weight and height at 6.5 years with atopy phenotypes**

There were positive associations of current weight, current height and current weight adjusted for current height with wheeze and allergic rhinitis (Table 5). There was evidence of a positive association of current weight adjusted for height with skin prick test results, and height at 6.5 years was negatively associated with ever having eczema

### **Mediation of associations between early weight and length/height gain and atopy phenotypes by current weight and height at 6.5 years**

Associations of weight gain rates with ever having wheezed and ever having rhinitis were attenuated by the addition of weight and height at 6.5 years, but weight gain between 0 and 3 months remained positively associated with ever having wheeze, and weight gain rate between 12 and 60 months remained associated with skin prick test results (Model 4, Web Tables A and B).

## DISCUSSION

Overall, no consistent patterns of association were found for weight and length/height gain rates from early-infancy to mid-childhood atopy phenotypes. There was evidence of an association of weight and length gain between 0 and 3 months with ever having allergic rhinitis, and evidence of an association of weight gain between 0 and 3 months, and length gain between 12 and 34 months with wheeze ever.

Associations of weight and height/length gain between 0 and 60 months with atopy phenotypes were consistent with those of current weight and height at 6.5 years with atopy phenotypes, but associations with current weight and height were larger in magnitude, even after controlling for previous growth. These results suggest that while current weight and/or height are associated with wheeze, eczema, allergic rhinitis and skin prick test results, the trajectory by which current size is reached is less relevant.

### Strengths and limitations

Strengths of the analytical approach have been previously outlined.<sup>45</sup> Good follow-up rates and few differences between included and excluded participants make selection bias unlikely. We identified biological trajectories prior to analysis, rather than conducting analyses at multiple time points and then choosing *post hoc* to highlight those with the largest associations with atopy phenotypes. Our study sample was large, providing sufficient power to detect associations in outcome categories with the fewest cases such as wheeze and asthma in the last 12 months and other atopy phenotypes, and allowing us to test for an interaction by sex.

Several limitations to our study merit discussion. First, we must be cautious about inferring causality from observational analyses. We were unable to adjust for some potential confounders such as early viral infections and food allergies. Nevertheless, associations of weight and length/height gain with atopy phenotypes were only slightly attenuated after controlling for a number of potential key confounders, and the degree of attenuation (0–5%) suggests that residual confounding, although a theoretical possibility, probably does not fully explain the results.

Second, methods for measuring length/height and weight before age 6.5 years were not standardized, which could have increased measurement error and reduced the precision of our estimates. Such measurement error is likely to have been non-differential, however, and therefore should have attenuated associations towards the null.

Third, all children in the PROBIT trial weighed at least 2500g at birth, were born at term and initiated breastfeeding. Therefore our findings may not be generalisable to preterm infants or to formula-fed infants.<sup>46,47</sup> Generalisability of our findings outside of Eastern Europe may also be limited, given the relatively low prevalence of atopy in Eastern European countries.<sup>48,49</sup>

Fourth, all outcomes except for skin prick tests were self reported, although based on a widely used and validated questionnaire.<sup>50</sup> As wheeze is a common symptom of respiratory infection, reported wheeze categories are likely to include children with both transient and persistent wheezing. There are also limitations when diagnosing asthma, particularly in children.<sup>51 52</sup> Consequently, reported asthma and wheeze categories are likely to be heterogeneous and potentially bias associations towards the null.

Fifth, we cannot rule out the possibility of reverse causality. Children whose parents answered ‘yes’ to questions enquiring about symptoms in the last 12 months may include

those who had symptoms first appear during this 12 month period, but also those who had symptoms before and throughout the 12 month period. Thus the weight and length/height gain exposures may not precede the occurrence of wheeze, asthma and atopic symptoms. The associations found between current weight and height and atopic outcomes may well be due to reverse causality (i.e. the development of asthma or atopy causing weight gain), as it seems unlikely that weight or height at 6.5 years could cause an atopic phenotypes that developed a few years earlier. Another potential explanation for these associations may be that there is residual confounding by an unknown common cause of both childhood growth trajectories and of atopy.

### Comparison with other studies including term-infants

Prevalence of reported asthma in our study was relatively low at 1.2% compared to the ranges of asthma prevalences reported in other Northern and Eastern European countries (5.0–13.6%). However, the prevalence's of rhinitis ever (4.5%) and rhinitis in the last 12 months (3.2%) reported in our study are similar.<sup>11</sup> Findings from relevant studies regarding associations of childhood growth with asthma and other atopic outcomes have been inconclusive. In line with our findings, one relatively small study (n=197) reported no evidence of an association of early life weight gain (birth to 2/3years) with daily asthma symptoms, pulmonary function, and eczema during pre-school years,<sup>28</sup> and a larger study reported no evidence of associations for length/height gains between birth and 12 months with wheeze or atopy at 3 years.<sup>23</sup> As in our study, the likely non-homogeneity of the outcome groups may have weakened any associations between risk factors and outcomes, and power was limited due to small subgroup numbers (n≈150). Pike et al reported evidence of a positive association for greater weight gains between birth and 12 months with atopic and non-atopic wheeze at age 3.<sup>23</sup> However, they highlighted that there were missing data for some confounding influences, notably maternal atopic status, meaning this association may be confounded. In line with our findings, accelerated weight gain from birth to 3 months following normal fetal growth has been associated with increased risks of asthma symptoms.<sup>25</sup> In a smaller study (n=131) higher rates of early infancy weight gain (5-14 weeks) were associated with impaired lung development, and in contrast, postnatal weight gain was not related to total respiratory compliance and only weakly related to FEV<sub>0.4</sub>.<sup>24</sup> This suggests that particular aspects of growth may have differing effects on these components of lung development; however, chance may also explain these findings. In contrast to our findings, several studies have reported cross-sectional associations of weight with asthma.<sup>29–33</sup> However, in our study the prevalence of asthma was low which may, in part, explain the wide confidence intervals observed for the estimates of the association between current weight, height adjusted current weight and asthma. To our knowledge, no other studies have included postnatal weight or length/height gain as an exposure with allergic rhinitis as an outcome.

### CONCLUSION

We found no evidence of consistent associations of infant to mid-childhood weight and length/height gain with atopy phenotypes, although there was weak evidence for an association of weight and length gain rate between 0–3 months with ever having allergic rhinitis and evidence of an association of weight gain rate between 0 and 3 months and length gain rate between 12 and 34 months with wheeze ever. Evidence of associations of current weight and/or height at 6.5 years with all atopy outcomes except for asthma ever, even after adjusting for previous growth velocity, suggests that current size is associated with wheeze and atopy, irrespective of the pattern or rate of preceding childhood weight and height/length growth, and this is likely to be due to reverse causality or residual confounding.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

The additional contributing members of the PROBIT Study Group are named. National Research and Applied Medicine Mother and Child Centre (Minsk, Belarus): Natalia Bazulko, Olga Gritsenko, Lidia Ovchinnikova, and Julia Rizkovskaya. Polyclinic paediatricians: Drs Natalia Andreeva (Rogachev), Tatiana Avdeichuk (Brest), Elena Avsiuk (Vitebsk), Irina Baikevich (Slonim), Zinaida Bisucova (Zlobin), Irina Bujko (Oshmiany), Tamara Galushkina (Volkovysk), Marina Gotovchi (Brest), Danuta Iodkovskaya (Berestovitsa), Galina Ivanova (Mogilev), Larisa Kebikova (Minsk), Galina Kluchnikova (Ostrovets), Maria Kotliarovich (Soligorsk), Galina Kovalevskaya (Lepel), Natalia Krokas (Mosty), Nadezda Kushkova (Rechitsa), Afanasia Lazarenko (Klimovichi), Ludmila Lazuta (Minsk), Zinaida Liamkina (Borisov), Raisa Lisiura (Stolin), Tamara Nabedo (Novolukoml), Svetlana Pleskach (Baranovichi), Oksana Potapenko (Soligorsk), Svetlana Pridhodorskaya (Berezuza), Valentina Rahotskaya (Oshmiany), Irina Rogach (Mstislavl), Ludmila Rutkovskaya (Kobrin), Natalia Senchuk (Rechitsa), Elena Seraia (Baranovichi), Ludmila Sheveleva (Kobrin), Vera Shota (Svisloch), Anna Silvanovich (Shuchin), Lilia Smolskaya (Glubokoe), Valentina Solovey (Volkovysk), Zoya Solovyova (Dokshitsy), Natalia Tsarik (Svetlogorsk), Nadezda Turkovskaya (Zlobin), and Oxana Zarodova (Minsk Region).

**Funding:** Abigail Fraser is funded by a UK Medical Research Council research fellowship (Grant ref: 0701594). The UK Medical Research Council and the University of Bristol provide core funding for the MRC Centre of Causal Analyses in Translational Epidemiology and Emma Anderson is funded by a MRC CAiTE studentship (Grant ref: G0600705). The original PROBIT trial and initial 12 months follow-up was funded by the Canadian National Health Research and Development Program, Thrasher Research Fund and UNICEF (to MSK). PROBIT is currently supported by grants from the Canadian Institutes of Health Research (grant number: MOP 53155 to MK), the European Union's project on Early Nutrition Programming: Long-term Efficacy and Safety Trials (grant code: FOOD-DT-2005-007036 to RMM) and the USA National Institutes of Health (R01 HD 050758 to EO and RMM). None of the funding bodies influenced the data collection, analysis or its interpretation for this paper. The views expressed are those of the authors and not necessarily any funding body.

## Reference List

1. Eder W, Ege MJ, Von Mutius E. The asthma epidemic. *N Engl J Med*. 2006 Nov 23; 355(21):2226–2235. [PubMed: 17124020]
2. Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. *J Allergy Clin Immunol*. 1999 Jan; 103(1 Pt 1):125–138. [PubMed: 9893196]
3. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax*. 2007 Sep; 62(9):758–766. [PubMed: 17504817]
4. Burr ML, Wat D, Evans C, Dunstan FD, Doull IJ. Asthma prevalence in 1973, 1988 and 2003. *Thorax*. 2006 Apr; 61(4):296–299. [PubMed: 16396947]
5. Zollner IK, Weiland SK, Piechotowski I, Gabrio T, Von Mutius E, Link B, et al. No increase in the prevalence of asthma, allergies, and atopic sensitisation among children in Germany: 1992–2001. *Thorax*. 2005 Jul; 60(7):545–548. [PubMed: 15994260]
6. Robertson CF, Roberts MF, Kappers JH. Asthma prevalence in Melbourne schoolchildren: have we reached the peak? *Med J Aust*. 2004 Mar 15; 180(6):273–276. [PubMed: 15012564]
7. Selnes A, Nystad W, Bolle R, Lund E. Diverging prevalence trends of atopic disorders in Norwegian children. Results from three cross-sectional studies. *Allergy*. 2005 Jul; 60(7):894–899. [PubMed: 15932379]
8. Wang HY, Pizzichini MMM, Becker AB, Duncan JM, Ferguson AC, Greene JM, et al. Disparate geographic prevalences of asthma, allergic rhinoconjunctivitis and atopic eczema among adolescents in five Canadian cities. *Pediatric Allergy and Immunology*. 2010; 21(5):867–877. [PubMed: 20492543]
9. Montefort S, Ellul P, Montefort M, Caruana S, Agius Muscat H. A decrease in the prevalence and improved control of allergic conditions in 13- to 15-yr-old Maltese children (ISAAC). *Pediatric Allergy and Immunology*. 2011; 22(1pt2):e107–e111. [PubMed: 20961337]

10. Selcuk ZT, Demir AU, Tabakoglu E, Caglar T. Prevalence of asthma and allergic diseases in primary school children in Edirne, Turkey, two surveys 10-áyears apart. *Pediatric Allergy and Immunology*. 2010; 21(4p2):e711–e717. [PubMed: 20337965]
11. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet*. 2006 Aug 26; 368(9537):733–743. [PubMed: 16935684]
12. Nepomnyaschy L, Reichman NE. Low birthweight and asthma among young urban children. *Am J Public Health*. 2006 Sep; 96(9):1604–1610. [PubMed: 16873737]
13. Kindlund K, Thomsen SF, Stensballe LG, Skytthe A, Kyvik KO, Backer V, et al. Birth weight and risk of asthma in 3–9-year-old twins: exploring the fetal origins hypothesis. *Thorax*. 2010 Feb; 65(2):146–149. [PubMed: 19996338]
14. Seidman DS, Laor A, Gale R, Stevenson DK, Danon YL. Is low birth weight a risk factor for asthma during adolescence? *Archives of Disease in Childhood*. 1991 May 1; 66(5):584–587. [PubMed: 2039246]
15. Brooks AM, Byrd RS, Weitzman M, Auinger P, McBride JT. Impact of Low Birth Weight on Early Childhood Asthma in the United States. *Arch Pediatr Adolesc Med*. 2001 Mar 1; 155(3):401–406. [PubMed: 11231809]
16. Remes ST, Patel SP, Hartikainen AL, Jarvelin MR, Pekkanen J. High birth weight, asthma and atopy at the age of 16 yr. *Pediatr Allergy Immunol*. 2008 Sep; 19(6):541–543. [PubMed: 18208461]
17. Leadbitter P, Pearce N, Cheng S, Sears MR, Holdaway MD, Flannery EM, et al. Relationship between fetal growth and the development of asthma and atopy in childhood. *Thorax*. 1999 Oct 1; 54(10):905–910. [PubMed: 10491453]
18. Bolte G, Schmidt M, Maziak W, Keil U, Nasca P, Von Mutius E, et al. The relation of markers of fetal growth with asthma, allergies and serum immunoglobulin E levels in children at age 5–7 years. *Clinical & Experimental Allergy*. 2004; 34(3):381–388. [PubMed: 15005731]
19. Yuan W, Basso O, Sorensen HT, Olsen J. Fetal growth and hospitalization with asthma during early childhood: a follow-up study in Denmark. *International Journal of Epidemiology*. 2002 Dec 1; 31(6):1240–1245. [PubMed: 12540729]
20. Balfour-Lynn L. Growth and childhood asthma. *Archives of Disease in Childhood*. 1986 Nov 1; 61(11):1049–1055. [PubMed: 3098185]
21. Ninan TK, Russell G. Asthma, inhaled corticosteroid treatment, and growth. *Archives of Disease in Childhood*. 1992 Jun 1; 67(6):703–705. [PubMed: 1626989]
22. Martin AJ, Landau LI, Phelan PD. The effect on growth of childhood asthma. *Acta Paediatrica*. 1981; 70(5):683–688.
23. Pike KC, Crozier SR, Lucas JS, Inskip HM, Robinson S, Roberts G, et al. Patterns of fetal and infant growth are related to atopy and wheezing disorders at age 3 years. *Thorax*. 2010 Dec; 65(12):1099–1106. [PubMed: 20956394]
24. Lucas JS, Inskip HM, Godfrey KM, Foreman CT, Warner JO, Gregson RK, et al. Small size at birth and greater postnatal weight gain: relationships to diminished infant lung function. *Am J Respir Crit Care Med*. 2004 Sep 1; 170(5):534–540. [PubMed: 15172897]
25. Sonnenschein-van der Voort A, Jaddoe VWV, Raat H, Moll HtA, Hofman A, de Jongste JC, et al. Fetal and Infant Growth and Asthma Symptoms in Preschool Children. The Generation R Study. *Am J Respir Crit Care Med*. 2012 Jan 20.
26. Canoy D, Pekkanen J, Elliott P, Pouta A, Laitinen J, Hartikainen AL, et al. Early growth and adult respiratory function in men and women followed from the fetal period to adulthood. *Thorax*. 2007 May; 62(5):396–402. [PubMed: 17105780]
27. Hancox RJ, Poulton R, Greene JM, McLachlan CR, Pearce MS, Sears MR. Associations between birth weight, early childhood weight gain and adult lung function. *Thorax*. 2009 Mar; 64(3):228–232. [PubMed: 19052051]
28. Paul IM, Camera L, Zeiger RS, Guilbert TW, Bacharier LB, Taussig LM, et al. *Pediatr Allergy Immunol*. 2010 Feb; 21(1 Pt 1):82–89. [PubMed: 19725894]



29. Figueroa-Muñoz J, Chinn S, Rona RJ. Association between obesity and asthma in 4–11 year old children in the UK. *Thorax*. 2001 Feb 1; 56(2):133–137. [PubMed: 11209102]
30. Luder E, Melnik TA, DiMaio M. Association of being overweight with greater asthma symptoms in inner city black and Hispanic children. *The Journal of Pediatrics*. 1998 Apr; 132(4):699–703. [PubMed: 9580773]
31. Von Mutius E, Schwartz J, Neas LM, Dockery D, Weiss ST. Relation of body mass index to asthma and atopy in children: the National Health and Nutrition Examination Study III. *Thorax*. 2001 Nov 1; 56(11):835–838. [PubMed: 11641506]
32. Tantisira KG, Litonjua AA, Weiss ST, Fuhlbrigge AL. Association of body mass with pulmonary function in the Childhood Asthma Management Program (CAMP). *Thorax*. 2003 Dec 1; 58(12):1036–1041. [PubMed: 14645968]
33. Von Kries R, Hermann M, Grunert VP, Von Mutius E. Is obesity a risk factor for childhood asthma? *Allergy*. 2001; 56(4):318–322. [PubMed: 11284799]
34. Kramer MS, Chalmers B, Hodnett ED, Sevkovskaya Z, Dzikovich I, Shapiro S, et al. Promotion of Breastfeeding Intervention Trial (PROBIT) A Randomized Trial in the Republic of Belarus. *JAMA: The Journal of the American Medical Association*. 2001 Jan 24; 285(4):413–420. [PubMed: 11242425]
35. Kramer MS, Vanilovich I, Matush L, Bogdanovich N, Zhang X, Shishko G, et al. The effect of prolonged and exclusive breast-feeding on dental caries in early school-age children. New evidence from a large randomized trial. *Caries Res*. 2007; 41(6):484–488. [PubMed: 17878730]
36. Kramer MS, Matush L, Vanilovich I, Platt R, Bogdanovich N, Sevkovskaya Z, et al. Effect of prolonged and exclusive breast feeding on risk of allergy and asthma: cluster randomised trial. *BMJ*. 2007 Oct 20.335(7624):815. [PubMed: 17855282]
37. Kramer MS, Aboud F, Mironova E, Vanilovich I, Platt RW, Matush L, et al. Breastfeeding and child cognitive development: new evidence from a large randomized trial. *Arch Gen Psychiatry*. 2008 May; 65(5):578–584. [PubMed: 18458209]
38. Kramer MS, Matush L, Vanilovich I, Platt RW, Bogdanovich N, Sevkovskaya Z, et al. Effects of prolonged and exclusive breastfeeding on child height, weight, adiposity, and blood pressure at age 6.5 y: evidence from a large randomized trial. *Am J Clin Nutr*. 2007 Dec; 86(6):1717–1721. [PubMed: 18065591]
39. Kramer MS, Fombonne E, Igumnov S, Vanilovich I, Matush L, Mironova E, et al. Effects of prolonged and exclusive breastfeeding on child behavior and maternal adjustment: evidence from a large, randomized trial. *Pediatrics*. 2008 Mar; 121(3):e435–e440. [PubMed: 18310164]
40. Tilling K, Davies NM, Nicoli E, Ben-Shlomo Y, Kramer MS, Patel R, et al. Associations of growth trajectories in infancy and early childhood with later childhood outcomes. *The American Journal of Clinical Nutrition*. 2011 Jul 1.
41. Tilling K, Howe LD, Ben-Shlomo Y. Commentary: Methods for analysing life course influences on health-untangling complex exposures. *International Journal of Epidemiology*. 2011 Feb 1; 40(1):250–252. [PubMed: 21216745]
42. Tilling K, Davies N, Windmeijer F, Kramer MS, Bogdanovich N, Matush L, et al. Is infant weight associated with childhood blood pressure? Analysis of the Promotion of Breastfeeding Intervention Trial (PROBIT) cohort. *International Journal of Epidemiology*. 2011 Oct 1; 40(5):1227–1237. [PubMed: 22039193]
43. Tilling K, Davies NM, Nicoli E, Ben-Shlomo Y, Kramer MS, Patel R, et al. Associations of growth trajectories in infancy and early childhood with later childhood outcomes. *The American Journal of Clinical Nutrition*. 2011 Jul 1.
44. Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, et al. Illustrating bias due to conditioning on a collider. *International Journal of Epidemiology*. 2010 Apr 1; 39(2):417–420. [PubMed: 19926667]
45. Ben-Shlomo Y, McCarthy A, Hughes R, Tilling K, Davies D, Smith GD. Immediate postnatal growth is associated with blood pressure in young adulthood: the Barry Caerphilly Growth Study. *Hypertension*. 2008 Oct; 52(4):638–644. [PubMed: 18768401]

46. Grischkan J, Storfer-Isser A, Rosen CL, Larkin EK, Kirchner HL, South A, et al. Variation in childhood asthma among former preterm infants. *J Pediatr*. 2004 Mar; 144(3):321–326. [PubMed: 15001935]
47. Mai XM, Gaddlin PO, Nilsson L, Leijon I. Early rapid weight gain and current overweight in relation to asthma in adolescents born with very low birth weight. *Pediatr Allergy Immunol*. 2005 Aug; 16(5):380–385. [PubMed: 16101929]
48. Matricardi PM. Prevalence of atopy and asthma in eastern versus western Europe: why the difference? *Annals of Allergy, Asthma & Immunology*. 2001 Dec; 87 Supplement 1(6):24–27.
49. Beasley R. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. *The Lancet*. 1998 Apr 25; 351(9111):1225–1232.
50. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. *European Respiratory Journal*. 1995 Mar 1; 8(3):483–491. [PubMed: 7789502]
51. Werk LN, Steinbach S, Adams WG, Bauchner H. Beliefs About Diagnosing Asthma in Young Children. *Pediatrics*. 2000 Mar 1; 105(3):585–590. [PubMed: 10699113]
52. Hargreave FE, Nair P. The definition and diagnosis of Asthma. *Clinical & Experimental Allergy*. 2009; 39(11):1652–1658. [PubMed: 19622089]

Table 1

## Sample characteristics

	Participants included in our analysis			Excluded participants			
	Girls N = 5865	Boys N = 6306	Total/combined N=12,171	N with data	Total combined N=4875	N with data	P
<b>Mothers' education</b>							
Completed university	825 (14.07)	868 (13.76)	1693 (13.91)		137 (8.24)		
Advanced secondary/partial university	3045 (51.92)	3270 (51.86)	6315 (51.89)	12,171	750 (45.10)	1663	<0.001
Common secondary	1,803 (30.74)	1982 (31.43)	3785 (31.10)		644 (38.73)		
Incomplete secondary	192 (3.27)	186 (2.95)	378 (3.11)		132 (7.94)		
<b>Mothers' anthropometry</b>							
Weight, kg (SD)	66.41 (12.60)	66.27 (12.48)	66.34 (12.54)		65.32 (12.56)	1601	<0.01
Height, cm (SD)	164.47 (5.64)	164.30 (5.62)	164.38 (5.63)	12,171	164.46 (5.71)	1563	0.59
BMI, kg/m <sup>2</sup> (SD)	24.53 (4.41)	24.53 (4.37)	24.53 (4.39)		23.85 (4.01)	1557	<0.001
<b>Fathers' education</b>							
Completed university	771 (13.15)	848 (13.45)	1619 (13.30)		100 (8.35)		
Advanced secondary/partial university	2797 (47.69)	2984 (47.32)	5781 (47.50)	12,171	572 (47.75)	1198	<0.001
Common secondary	2176 (37.10)	2339 (37.09)	4515 (37.10)		463 (38.65)		
Incomplete secondary	121 (2.06)	135 (2.14)	256 (2.10)		63 (5.26)		
<b>Fathers' anthropometry</b>							
Weight, kg (SD)	79.57 (11.50)	79.89 (11.37)	79.74 (11.43)		88.54 (12.86)	690	<0.001
Height, cm (SD)	175.97 (6.64)	176.12 (6.61)	176.05 (6.63)	12,171	176.31 (7.28)	366	0.46
BMI, kg/m <sup>2</sup> (SD)	25.67 (3.26)	25.74 (3.27)	25.71 (3.26)		25.28 (3.20)	339	0.02
<b>Outcomes at mean age 6.5 years</b>							
Wheezed ever	487 (8.30)	771 (12.23)	1258 (10.34)	12,169	171 (10.11)	1691	0.08
Wheezed in the last 12 months	150 (2.56)	222 (3.52)	372 (3.06)	12,167	54 (3.19)	1691	0.76
Allergic rhinitis ever	231 (3.94)	313 (4.96)	544 (4.47)	12,169	97 (5.74)	1691	0.02
Allergic rhinitis in the last 12 months	165 (2.81)	221 (3.50)	386 (3.17)	12,171	68 (4.02)	1691	0.07
Eczema ever	56 (0.96)	66 (1.05)	122 (1.00)	12,159	19 (1.12)	1689	0.64
Asthma ever	54 (0.92)	87 (1.38)	141 (1.16)	12,171	24 (1.42)	1691	0.35
Positive skin prick test results	1036 (21.99)	1153 (22.72)	2189 (22.37)	9787	318 (23.63)	1346	0.30

	Participants included in our analysis				Excluded participants		
	Girls N = 5865	Boys N = 6306	Total/combined N=12,171	N with data	Total combined N=4875	N with data	P
Family history of atopy	182 (3.10)	190 (3.01)	372 (3.06)		176 (3.61)	4875	0.06
Urban residence	3,187 (54.34)	3,470 (55.03)	6,657 (54.70)		3,340 (68.51)	4875	<0.001
Treatment Arm	2966 (50.57)	3163 (50.16)	6129 (50.36)		2736 (56.12)	4875	<0.001
Maternal age (SD)	25.14 (4.90)	25.05 (4.86)	25.09 (4.88)		24.45 (5.00)	4874	<0.001
Exclusive Breastfeeding at 3 months	1593 (27.16)	1678 (26.61)	3271 (26.88)	12,171	1212 (24.86)	4875	<0.01
Mean Birth weight, kg (SD)	3.38 (0.40)	3.52 (0.42)	3.45 (0.42)		3.41 (0.42)	4875	<0.001
Mean Birthlength, cm (SD)	51.66 (2.05)	52.36 (2.18)	52.02 (2.15)		51.75 (2.12)	4875	<0.001
Mean weight at 6.5 years, kg(SD)	22.51 (3.65)	23.08 (3.58)	22.80 (3.62)		22.75 (3.59)	1657	0.55
Mean height at 6.5 years, cm (SD)	120.50 (5.24)	120.89 (5.13)	120.70 (5.18)		120.35 (5.14)	1656	<0.01

SD = standard deviation. P values for the differences between included and excluded participants were calculated using unpaired t-tests for continuous variables and chi-squared tests for categorical variables.

**Table 2**

Weight and length/height at birth and weight and length/height velocities from 3 months to 5 years from multilevel spline models for weight and length/height with age.

	Girls (N=5050)		Boys (N=5444)	
	Mean (SD)	95% reference range	Mean (SD)	95% reference range
Birth weight (kg)	3.33 (1.01)	1.48, 5.48	3.42 (1.00)	1.55, 5.46
0–3 month velocity (kg/year)	10.80 (0.99)	8.99, 12.94	11.89 (0.98)	10.17, 13.99
3–12 month velocity (kg/year)	6.10 (1.00)	4.26, 8.25	6.10 (1.00)	4.29, 8.28
12–34 month velocity (kg/year)	1.90 (1.05)	0.04, 4.34	1.90 (1.04)	0.06, 4.25
34–60 month velocity (kg/year)	2.11 (1.02)	0.30, 4.51	2.09 (1.01)	0.35, 4.39
Birthlength (cm)	51.42 (1.01)	49.62, 53.70	52.03 (1.00)	50.32, 54.18
0–3 month velocity (cm/year)	36.19 (0.99)	34.28, 38.17	38.57 (0.99)	36.59, 40.56
3–12 month velocity (cm/year)	20.51 (1.01)	18.53, 22.49	20.38 (1.01)	18.31, 22.28
12–34 month velocity (cm/year)	9.70 (1.04)	7.46, 11.86	9.70 (1.04)	7.50, 11.87
34–60 month velocity (cm/year)	7.40 (1.02)	5.27, 9.77	7.40 (1.02)	5.28, 9.48

Associations of early-infancy to mid-childhood weight gain rate (gender adjusted z-score) with wheeze, eczema, allergic rhinitis and skin prick test results at 6.5 years, in the fully adjusted model <sup>†</sup>

**Table 3**

Outcome	Birth weight			Growth 0–3 months			Growth 3–12 months			Growth 12–34 months			Growth 34–60 months		
	OR <sup>1</sup>	95%CI	P	OR <sup>2</sup>	95%CI	P	OR <sup>2</sup>	95%CI	P	OR <sup>2</sup>	95%CI	P	OR <sup>2</sup>	95%CI	P
Wheeze ever	1.02	(0.93,1.11)	0.73	1.12	(1.05,1.19)	<0.01	1.05	(0.99,1.12)	0.11	1.08	(1.01,1.15)	0.02	1.03	(0.94,1.13)	0.49
Wheeze in the last 12 months	1.13	(0.97,1.32)	0.11	1.06	(0.95,1.18)	0.28	1.07	(0.95,1.19)	0.26	1.08	(0.97,1.20)	0.16	0.93	(0.80,1.09)	0.37
Asthma ever	1.11	(0.88,1.40)	0.38	1.12	(0.95,1.32)	0.19	1.15	(0.96,1.36)	0.13	1.00	(0.84,1.18)	0.95	1.01	(0.80,1.28)	0.93
Allergic rhinitis ever	0.96	(0.85,1.10)	0.56	1.11	(1.02,1.22)	0.02	1.06	(0.97,1.17)	0.21	1.08	(0.99,1.18)	0.09	0.92	(0.80,1.05)	0.22
Allergic rhinitis in the last 12 months	0.97	(0.84,1.13)	0.74	1.10	(0.99,1.22)	0.06	1.10	(0.98,1.22)	0.10	1.06	(0.96,1.18)	0.25	0.95	(0.81,1.11)	0.51
Eczema ever	1.01	(0.78,1.31)	0.93	1.10	(0.92,1.32)	0.30	0.85	(0.70,1.04)	0.12	0.97	(0.80,1.18)	0.76	1.04	(0.78,1.38)	0.80
Positive skin prick test result	1.01	(0.93,1.09)	0.83	1.02	(0.96,1.08)	0.48	1.04	(0.98,1.10)	0.18	0.93	(0.88,0.99)	0.02	1.08	(1.00,1.17)	0.05

OR<sup>1</sup> = odds of outcome per z-score increase in birth weight

OR<sup>2</sup> = odds of outcome per z-score change in weight gain

<sup>†</sup> Adjusted for clustering by clinic; confounders: sex, treatment arm, exclusive breastfeeding at 3 months, parents' height and weight, mother's age, family history of atopy and parent's education and preceding weight and length/height

Associations of early-infancy to mid-childhood length/height gain rate (gender adjusted z-score) with wheeze, eczema, allergic rhinitis and skin prick test results at 6.5 years, in the fully adjusted model <sup>†</sup>

**Table 4**

Outcome	Birth length			Growth 0–3 months			Growth 3–12 months			Growth 12–34 months			Growth 34–60 months		
	OR <sup>1</sup>	95%CI	P	OR <sup>2</sup>	95%CI	P	OR <sup>2</sup>	95%CI	P	OR <sup>2</sup>	95%CI	P	OR <sup>2</sup>	95%CI	P
Wheeze ever	0.97	(0.89,1.07)	0.57	0.99	(0.92,1.06)	0.75	0.98	(0.91,1.05)	0.49	1.08	(1.01,1.15)	0.03	1.05	(0.98,1.12)	0.19
Wheeze in the last 12 months	0.90	(0.77,1.06)	0.21	1.08	(0.96,1.22)	0.19	0.99	(0.88,1.13)	0.93	0.96	(0.85,1.07)	0.46	1.02	(0.90,1.14)	0.78
Asthma ever	1.07	(0.84,1.37)	0.56	1.00	(0.82,1.21)	0.99	1.07	(0.87,1.30)	0.53	0.97	(0.81,1.16)	0.75	0.92	(0.77,1.11)	0.38
Allergic rhinitis ever	1.07	(0.94,1.23)	0.31	1.11	(1.01,1.23)	0.04	1.05	(0.95,1.17)	0.32	1.04	(0.94,1.14)	0.46	0.94	(0.85,1.04)	0.26
Allergic rhinitis in the last 12 months	1.05	(0.90,1.23)	0.54	1.10	(0.98,1.24)	0.12	1.03	(0.91,1.16)	0.63	1.08	(0.96,1.20)	0.20	0.91	(0.81,1.03)	0.15
Eczema ever	1.09	(0.83,1.42)	0.55	0.96	(0.78,1.18)	0.66	0.92	(0.74,1.13)	0.41	1.08	(0.89,1.32)	0.41	1.10	(0.90,1.36)	0.34
Positive skin prick test result	1.09	(0.83,1.42)	0.55	0.96	(0.78,1.18)	0.66	0.92	(0.74,1.13)	0.41	1.08	(0.89,1.32)	0.41	1.10	(0.90,1.36)	0.34

OR<sup>1</sup> = odds of outcome per z-score increase in birth length

OR<sup>2</sup> = odds of outcome per z-score change in length/height gain

<sup>†</sup> Adjusted for clustering by clinic; confounders: sex, treatment arm, exclusive breastfeeding at 3 months, parents' height and weight, mother's age, family history of atopy and parent's education; birth weight and preceding length/height measures.

**Table 5**

Associations of current weight and height (gender adjusted z-score) at 6.5 years with wheeze, eczema, allergic rhinitis and skin prick test results at 6.5 years, adjusted for clustering by clinic, confounders<sup>1</sup> and previous weight and height measurements

Outcome	Current weight <sup>1</sup>			Height adjusted current weight <sup>2</sup>			Current height <sup>3</sup>		
	OR <sup>2</sup>	95%CI	P	OR <sup>2</sup>	95%CI	P	OR <sup>2</sup>	95%CI	P
<b>Wheeze ever</b>	1.07	(0.99,1.16)	0.09	1.12	(1.01,1.23)	0.03	1.10	(1.01,1.19)	0.04
<b>Wheeze in the last 12 months</b>	1.15	(1.00,1.31)	0.05	1.16	(0.98,1.36)	0.07	1.16	(1.00,1.34)	0.06
<b>Asthma ever</b>	1.15	(0.92,1.42)	0.21	1.12	(0.86,1.46)	0.41	1.19	(0.93,1.51)	0.16
<b>Allergic rhinitis ever</b>	1.13	(1.01,1.26)	0.03	1.14	(0.99,1.31)	0.07	1.16	(1.02,1.32)	0.02
<b>Allergic rhinitis in the last 12 months</b>	1.14	(1.00,1.30)	0.06	1.16	(0.99,1.36)	0.07	1.17	(1.01,1.36)	0.04
<b>Eczema ever</b>	0.84	(0.65,1.09)	0.18	0.98	(0.72,1.35)	0.92	0.75	(0.59,0.97)	0.03
<b>Positive skin prick test result</b>	1.03	(0.95,1.11)	0.52	1.12	(1.02,1.23)	0.02	0.94	(0.87,1.02)	0.12

<sup>1</sup> Adjusted for clustering by clinic, confounders and all previous weight measurements

<sup>2</sup> Adjusted for clustering by clinic, current height, confounders and all previous weight and height measurements

<sup>3</sup> Adjusted for clustering by clinic, confounders and all previous height measurements and birthweight

<sup>4</sup> Adjusted for confounders: sex, age at outcome assessment, treatment arm, exclusive breastfeeding at 3 months, parents' height and weight, mothers' age, family history of atopy and parents' education